Germany-Japan Life Science Seminar "Why foreign Life Science industries choose Germany to invest for developing their business in EU?" - most up-to-date trends of the market

  • twitter
  • Facebook
  • LINE

*Japanese Page

The recent pandemic was a novel experience for Germany and had many implications for the healthcare system and industry. Investment in medical innovation rapidly rose and a number of technological breakthroughs could be achieved. For example, Germany‘s biotech and pharma industry has played a leading role in the development of mRNA vaccines, diagnostics and other solutions now used around the world. Also, the quickly rising number of doctors and patients embracing tools such as telemedicine, remote monitoring, electronic patient files, medical apps, and electronic prescriptions led to an accelerated adoption of digital solutions. Further to these, robotics and automation such as “da Vinch” and supply chain review as SCM become new drivers of German market.

In our presentation, we will introduce market numbers, key industry trends, and major investment programmes, together with market access, clinical studies, R&D and partnering in Germany for foreign companies such as Japanese and sharing the invaluable experience of a Japanese company operating in Germany.

Language:English, Japanese
*English captions are available (you can choose to turn them on or off).
*Please note that LINK-J and GTAI are not responsible for any errors or omissions in the captions.

How to use captions: Managing and viewing closed captioning

Date and Time

Mon, Sep 26, 4pm - 6:30pm (JST) / Mon, Sep 26, 9am-11:30am (CEST)


- In-person:Nihonbashi Life Science HUB
- Virtual:Zoom Webinar

Register here!

(Opens an external site)


JST Agenda
4:00-4:05pm Opening Remarks - Shunichi Takahashi, Secretary General, LINK-J
4:05-4:10 Introduction to GTAI and services for Japanese companies
- Hiroshi Iwamura, Representative of GTAI Tokyo
4:10-4:30 Presentation “Germany’s healthcare market, industry trends and investments”
- Marcus Schmidt, Director Chemicals & Healthcare, GTAI Berlin
4:30-4:50 Presentation “Sysmex strategic investment to German company of Partec GmbH and the management”
- Shinjirou Akamatsu, Executive Vice President, Global Management dividion, Sysmex Corporation
4:50-5:10 Presentation " Innovative medical technology, clinical studies, R&D, market access and partnering in Germany "
- Prof. Dr. Arndt-Peter Schulz, Consultant Medical Researcher, Associated Researcher Fraunhofer at University of Lübeck, Institute of Medical Engineering, Fraunhofer Research Institution for Individualized and Cell-Based Medical Engineering IMTE) [online]
5:10-5:30 Presentation "Exclusive preview of new studies and key events in Europe for biotechnology and medical device companies"
- Gregor Kemper, Project Manager, GTAI Berlin [online]
- Gabriel Flemming, Senior Manager Healthcare, GTAI Berlin [online]
5:30 Closing Remarks - H. Iwamura
5:30-6:30 Networking reception (In-person only)

*Mr. Iwamura, Dr. Schmidt, Mr. Akamatsu, and Dr. Takahashi will participate in the real venue, others will participate online.


Hiroshi Iwamura (revised)_150.pngHiroshi Iwamura(Representative of GTAI Tokyo)
・A professional whose background lies in risk advisory in HSBC, a global financial group and international economic research firms, but allied with considerable management experience working for over 20 years in the UK.
・Led a cross disciplinary and multinational team for the HSBC group focusing on the group strategy and performance leveraging the group’s synergy by analysing past performance and making recommendations for future improvement to the Holdings and approved.

Schmidt-Marcus_150.jpgMarcus Schmidt(Director Chemicals & Healthcare, GTAI Berlin)
Dr. Marcus Schmidt is the Director Chemicals & Healthcare at Germany Trade and Invest (GTAI), the foreign trade and inward investment agency of the Federal Republic of Germany. His industry group advises international companies expanding into Germany in the fields of
- medical technology
- e-health
- pharmaceuticals
- biotechnology
- consumer health
- elderly care

During the corona crisis, he and his team worked closely with the German federal ministries and other government agencies to secure supply of medical equipment and to encourage local production of critical supplies, such as protective masks and medications.

Dr. Schmidt has been involved with attracting foreign direct investment to Germany since 2000.
He held various roles with GTAI’s predecessor companies, the Industrial Investment Council and Invest in Germany. After working as a Project Manager in Berlin, he served as Director North America in New York and Washington, DC as well as the global Group Director for Technology & Services.

Dr. Schmidt received his Ph.D. in law from the University of Innsbruck, a Masters in law from the University of Muenster, and an MBA in International Industrial Management from the University of Applied Sciences in Esslingen, Germany. Prior to his career in economic development, Dr. Schmidt served in various legal positions in Germany and (briefly in) Japan.

akamatu_150.pngShinjirou Akamatsu(Executive Vice President, Global Management dividion, Sysmex Corporation)
Apr 1994: Joined Sysmex Corporation
Apr 2006: Managing Director, Sysmex do Brazil Ltd./Managed LATAM business and Reagent production factory
Oct 2010: Director, Business Strategy Development Division, Sysmex Corporation/Developped Hematology business strategy and Emerging Countory strategy
Oct 2013: President & CEO, Sysmex Partec GmbH/Managed FCM business and Instrument/Reagent production factory
Apr 2019: Senior Vice President, Business Strategy Development Division, Sysmex Corporation/Managed FCM business, Primarycare business and PLM(Product Lifecycle Management)
Apr 2021(Currect): Executive Vice President, Global Management Division, Sysmex Corporation/Charging for International Business Managenet and Global Technical service

Arndt-Peter Schulz_150.jpgArndt-Peter Schulz (Consultant Medical Researcher, Associated Researcher Fraunhofer at University of Lübeck, Institute of Medical Engineering, Fraunhofer Research Institution for Individualized and Cell-Based Medical Engineering IMTE)
ARNDT-PETER SCHULZ is a medical dochtor who studied at the University Hospital Hamburg Eppendorf. After surgical training in Germany and England, he started a position at the BG Trauma Hospital in Hamburg, followed by a position as consultant surgeon in orthopedics and trauma at the University Hospital Lübeck. His PhD thesis involved development of a surgical robot system for hip surgery. Next to his position, he led the department of biomechanics and was dean of physiotherapy for a few years. In 2020, he rejoined the BG Trauma Hospital in Hamburg. In 2021 he joined the Fraunhofer Research Institution for Individualized and Cell-Based Medical Engineering IMTE next to his position in Hamburg.

Kemper-Gregor_150.jpgGregor Kemper (Project Manager, GTAI Berlin)
Dr. Gregor Kemper studied Chemistry in Göttingen (Germany) and completed his graduate studies at the Universities of Bordeaux (France) and Waterloo (Canada) in the fields of Chemistry and Pharmacy with a research focus on the impact of bio-nanomaterials on stem cell differentiation. After working as an analyst in biopharma consulting and in a contract research business development role, he joined Germany Trade & Invest's Chemicals & Healthcare team in 2019. Mr. Kemper's current role is to assist international companies that intend to establish a subsidiary in Germany by providing information on various topics. His scientific knowledge and experience in business matters enable him to support companies from the medical biotechnology, pharma and diagnostics industry in their expansion to Germany and provide a basis for good decision making on their international operations.

Flemming-Gabriel_150.jpgGabriel Flemming (Senior Manager Healthcare, GTAI Berlin)
Gabriel has a Business Administration degree of the University of Munich Business School (LMU). Strategic management and marketing were his major fields of study as well as the economic system of Japan. Subsequently he held positions in sales and marketing at publishing companies and a B2B language service provider based in Hamburg, Germany. The German life sciences and healthcare sector became his industry focus during his time as an IP Acquisition Manager for a company managing the patent value funds of Deutsche Bank. In 2009 Gabriel joined Germany Trade & Invest (GTAI), the economic development agency of the Federal Republic of Germany. As a medical technology specialist in GTAI's Chemicals & Healthcare team his role Gabriel today is to assist companies in the medical technology sector to build up their presence in Germany, covering all sales, R&D or manufacturing driven business cases.

takahashi_trimmed_220630_150.pngShunichi Takahashi(Secretary General, LINK-J)

Participation fee



In-person: 150 people
*We reserve the right to change the event as a completely virtual format due to government requests or the status of the spread of COVID-19 infection. In such cases, please watch the webinar even if you have registered as an in-person attendee.

Virtual: 1000 people


Organizer:Germany Trade and Invest (GTAI)